03/06/2026 - Covid-19
You can now vote for her candidacy! The award is promoted by Fundació Catalunya La Pedrera and La Vanguardia. Aura Muntasell, researcher in the Immunity and Infection Research Group at the Hospital del Mar Research Institute and professor in the Department of Cell Biology at the Universitat Autònoma de Barcelona (UAB), is one of the eight finalists in the fifteenth edition of the Vanguardia Science Award, promoted by Fundació Catalunya La Pedrera and La Vanguardia. You can vote for your favourite finalist until 28 June.
Més informació "Aura Muntasell is one of the eight finalists for the Vanguardia Science Award"
The first patient trial of the device, which needs to be optimised before clinical application, shows its ability to identify a biomarker of this type of cancer in blood plasma using a low-cost, easy-to-use test strip. The prototype can distinguish the presence of the sAXL biomarker between samples from patients with pancreatic cancer and healthy individuals, indicating its potential application at the point of patient care.
18/05/2026 - Covid-19
An international study published in the journal Nature has designated a subset of the so-called dark proteins - proteins with no known function - as peptideins. Characterising them opens the door to studying them and analysing their functions. The TransCODE consortium, of which the Hospital del Mar Research Institute is the only research centre in Spain to be a member, has just published a new article that advances knowledge of the so-called dark genome, a part of the human genome that has not been studied and whose function is unknown. The journal Nature publishes the study, in which it designates thousands of previously unannotated proteins as peptideins.
22/04/2025 - Covid-19
A study led by the Hospital del Mar Research Institute, in collaboration with the Caldes de Montbui City Council, has validated the use of thermal waters to reduce some symptoms in people affected by long COVID. Balneotherapy helped improve pain and fatigue, with benefits that persisted after treatment ended. Improvements were also observed in sleep quality and anxiety, although these did not last over time. People with long COVID who underwent a one-month thermal water treatment program were twice as likely to improve their symptoms compared to those who did not receive the treatment.
Més informació "Balneotherapy Improves Various Symptoms of Long COVID"
11/03/2024 - Covid-19
This is revealed by a study at Hospital del Mar, which prospectively analyzed data from nearly 2,000 people followed at the center's Post-COVID Unit. The main risk factors for developing persistent COVID are obesity, asthma and the severity of the disease. Women are also at higher risk These results lead the authors of the study to consider antiviral treatment also for people with SARS-CoV-2 infection who meet these risk factors, even if they do not suffer from severe COVID.
Més informació "Treatment of COVID-19 with antivirals may protect from persistent COVID"
28/02/2024 - Covid-19
One of them is related to heart disease, according to the CARGENCORS study. The work has allowed finding a significant association of new genetic variants previously related to heart disease, thrombosis, inflammation, with the severity of COVID-19 in more than 3000 COVID-19 patients in the area of Barcelona and Girona. People with these variants have a 10-60% increased chance of developing severe disease. The CARGENCORS (CARdiovascular GENEtic risk score for Risk Stratification of patients positive for SARS-CoV-2 (COVID-19) virus) study has established a direct link between some of the genetic factors that increase the risk of heart disease and the severity of COVID-19. The work, published in the Journal of Medical Virology, marks a further step towards understanding the mechanisms of COVID-19 severity through susceptibility in heart disease.
Més informació "New genetic variants related to severe COVID-19 identified"
14/02/2024 - Covid-19
It is a monoclonal antibody with prophylactic and therapeutic action, isolated from blood samples of a patient infected by SARS-CoV-2 during the first wave of the pandemic. The antibody has been designed and developed by researchers from the Hospital del Mar Research Institute, the IrsiCaixa AIDS Research Institute, the National Center for Biotechnology and the Center for Genomic Regulation. In addition, this new treatment has been patented pending commercial development. This new treatment has been patented pending commercial development. The results of the work have been published in the journal Nature Communications.
Més informació "New antibody blocks all SARS-CoV-2 variants in preclinical models"
07/09/2023 - Covid-19
Overall, health has worsened across the population, especially regarding anxiety and depression, as well as pain and discomfort. But the effects of the pandemic have hit educated women especially hard, narrowing their health disparities with population groups with a lower education after initial home confinement. The researchers attribute this development to the negative effect of teleworking on the health of people who worked from home and had to care for family members. At the same time, there may have been a positive effect of government measures to mitigate the economic impact of the pandemic among more disadvantaged groups. The work is part of the MINDCOVID project, and was based on telephone interview surveys of 2,000 people. It is published in the International Journal for Equity in Health.
Més informació "COVID-19 has reduced health inequalities in Spain"
27/10/2022 - Covid-19
A study by the Hospital del Mar Medical Research Institute and Pompeu Fabra University has found that not all HIV patients respond adequately to the SARS-CoV-2 vaccine. The work has been published in the journal Frontiers in Immunology. Up to 20% of people with HIV being treated with antiretroviral drugs do not regain normal levels of immune cells in their blood. These people, with a depressed immune system, are considered to be at risk of SARS-CoV-2 infection and were prioritised in the COVID-19 vaccination strategy, just as other at-risk groups were. However, until now it was not known how they responded to immunisation with RNA-based vaccines, such as those from Pfizer and BioNTech.
04/07/2022 - Covid-19
The possibility of re-freezing vials once they are prepared may enable the manipulation of vaccines in the country of origin, freezing the syringes, and sending them to their destination for immediate use, without the need for a major infrastructure. The shelf life of the re-frozen vaccine is at least one month.
Servei de Comunicació:
Marta Calsina(ELIMINAR)
Tel:
(+34) 93 316 06 80
Doctor Aiguader, 88
08226 Barcelona
© Institut Hospital del Mar
d'Investigacions MèdiquesLegal Notice and Privacy Policy | Cookie Policy | Site Index | Accessibility | Find Us | Contact
